Philippines vs Togo: HIV/AIDS deaths averted by antiretroviral therapy
Philippines
5,500 deaths
in 2024
Togo
5,494 deaths
in 2024
Philippines rank
34th
Togo rank
35th
HIV/AIDS deaths averted by antiretroviral therapy over time
- Philippines
- Togo
How they compare
Philippines currently reports 5,500 deaths against 5,494 deaths in Togo, a difference of 6 deaths.
The two have swapped places 1 time across 35 shared years of data; in 1990 it was Togo ahead.
Philippines ranks 34th and Togo ranks 35th of 157 countries.
Togo has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Philippines | Togo | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0 deaths | 0 deaths | 0 deaths | — |
| 2000s | 23.06 deaths | 940.75 deaths | 917.69 deaths | Togo |
| 2010s | 1,105 deaths | 4,416 deaths | 3,311 deaths | Togo |
| 2020s | 4,288 deaths | 5,603 deaths | 1,315 deaths | Togo |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv/aids deaths averted by antiretroviral therapy, Philippines or Togo?
- Philippines, at 5,500 deaths against 5,494 deaths in Togo as of 2024.
- What is the difference in hiv/aids deaths averted by antiretroviral therapy between Philippines and Togo?
- 6 deaths, with Philippines ahead.
- How many years of comparable data are there for Philippines and Togo?
- 35 years are reported by both, from 1990 to 2024.
- How do Philippines and Togo rank globally for hiv/aids deaths averted by antiretroviral therapy?
- Philippines ranks 34th and Togo ranks 35th of 157 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as HIV/AIDS deaths averted by antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of deaths prevented as a direct result of Antiretroviral Therapy (ART) among people living with HIV. It is calculated by comparing the observed mortality rates in individuals receiving ART to the estimated mortality rates in the absence of such treatment. This is the central estimate.